Evidence map›Paper›PMID 26243289›Full record

ArticleRespiratory research2015

Quantitation of circulating wild-type alpha-1-antitrypsin in heterozygous carriers of the S and Z deficiency alleles.

L J Donato, R M Karras, J A Katzmann, D L Murray, M R Snyder

Open access · goldAbstract read
In one paragraph

Article in Respiratory research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Alpha-1-Antitrypsin (A1AT) Proteotyping by LC-MS/MS.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  3. Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide.International journal of chronic obstructive pulmonary disease · 2017
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

L J DonatoDepartment of Laboratory Medicine & Pathology Mayo Clinic, Mayo Clinic, 200 First St. SW, 55905, Rochester, MN, USA. donato.leslie@mayo.edu.
R M KarrasPresent address: University of Minnesota, Minneapolis, MN, USA. robinkarras@gmail.com.
J A KatzmannDepartment of Laboratory Medicine & Pathology Mayo Clinic, Mayo Clinic, 200 First St. SW, 55905, Rochester, MN, USA. katzmann@mayo.edu.
D L MurrayDepartment of Laboratory Medicine & Pathology Mayo Clinic, Mayo Clinic, 200 First St. SW, 55905, Rochester, MN, USA. Murray.David@mayo.edu.
M R SnyderDepartment of Laboratory Medicine & Pathology Mayo Clinic, Mayo Clinic, 200 First St. SW, 55905, Rochester, MN, USA. snyder.melissa@mayo.edu.
Mayo Clinic · USUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlpha-1-antitrypsin (A1AT) deficiency disease results from mutations in the A1AT gene. Controversy exists in regards to treatment of heterozygous carriers of the S and Z deficiency alleles. Quantitation of allelic expression has not been possible with standard laboratory methods. Here we show that the recently described method for liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis of A1AT tryptic peptides can differentiate between mutated (S and Z) and wild-type (non-S and non-Z) proteins allowing for quantitation of circulating allelic expression in heterozygous patients.

methodsSerum (244 M/M, 61 M/Z, and 63 M/S) was combined with isotopically labeled peptide standards, digested with trypsin, and quantitated by LC-MS/MS. Total and allele-specific A1AT quantitation was performed by comparison of peptide peak height ratios to a standard curve for each peptide. Linear regression was used to compare results and central 95(th) percentile intervals were calculated using parametric analysis.

resultsQuantitation of circulating wild-type A1AT based on the proteotypic and allelic (non-S and non-Z) peptides was validated in M/M patients. Proteotypic peptide concentrations correlated linearly with quantitation by non-Z and non-S peptides [slopes (Spearman correlation coefficient) of 1.09 (0.89) and 0.98 (0.80), respectively]. Allele-specific quantitation showed significant differences in wild-type protein expression in M/Z and M/S patients. Although average total A1AT concentration was lower for M/Z patients, the percentage of wild-type protein in M/Z patients was significantly higher at 82 % (55- > 95 %) compared to 63 % (43-83 %) for M/S heterozygotes. In a cohort of M/Z patients with sufficient total A1AT (≥80 mg/dL), half had insufficient wild-type protein that could have clinical implications for pulmonary dysfunction.

conclusionsFor the first time, a method to quantitate A1AT allele protein expression is described. Given the wide range of circulating wild-type protein observed in heterozygous patients, this method has the potential to reveal correlations between allele concentration and development and/or severity of clinical symptoms.

Indexed as

AllelesHeterozygotealpha 1-Antitrypsinalpha 1-Antitrypsin DeficiencyBiomarkersChromatography, LiquidFemaleHumansMaleTandem Mass Spectrometryalpha 1-AntitrypsinBiomarkersSERPINA1 protein, human

Identifiers

PMID26243289
PMCPMC4531808
OpenAlexW1885137394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.